| Document Date: 2015-04-16 10:43:32 Open Document File Size: 63,48 KBShare Result on Facebook
Company Theravance / Merck & Co Inc / Radius / Synageva / AbbVie / Gilead / Bacterial Pneumonia / Isis Pharmaceuticals / Pharmacyclics / Alnylam Pharmaceuticals / Cempra / Celgene / Alexion Pharmaceuticals / Tesaro / Media Relations Bellevue Asset Management AG / Incyte / Achillion / Infinity Pharmaceuticals / Medivation / Claude Mikkelsen / Vertex Pharmaceuticals / Halozyme Therapeutics / Actelion / Intercept / Tetraphase / Neurocrine Biosciences / Sanofi / Vertex / BB Biotech AG / Immunogen / Novo Nordisk / Novavax / Regeneron Pharmaceuticals / Investor Relations Bellevue Asset Management AG / Thomas Egger / / Country Switzerland / Germany / Italy / Japan / United States / / Currency CHF / USD / / / Event FDA Phase / Security Buyback / General or Shareholder Meeting / M&A / Dividend Issuance / / IndustryTerm biotechnology / chronic weight management / biotechnology investors / healthcare industry / biotechnology industry / bank actions / differentiated products / treatment of cystic fibrosis / treatment of chronic liver diseases / / MarketIndex S&P 500 / Nasdaq Biotech / / MedicalCondition Community Acquired Bacterial Pneumonia / Ryzodeg diabetes / congenital adrenal hyperplasia / hepatitis C / non-small cell lung cancer / cystic fibrosis / chronic weight management / non-alcoholic fatty liver disease / diabetes / chronic liver diseases / orphan disease primary biliary cirrhosis / / MedicalTreatment statin therapy / / NaturalFeature FLINT / / OperatingSystem Isis / / Organization European Central Bank / Swiss National Bank / FDA / / Person Maria-Grazia Iten-Alderuccio / Tanja Chicherio / Silvia Schanz / / / Product Gilead Actelion 10.7% 9.5 / Saxenda / / Technology alpha / biotechnology / / URL www.bbbiotech.com / /
SocialTag |